Perflubron emulsion is expected to be in clinical use soon as a non-hemoglobin blood substitute. A preliminary report indicates that this new oxygen-carrying fluorocarbon interferes with the measurements of COoximeters. Therefore, we have quantified the interference that perflubron causes in the measurements of eight widely used oximeters and CO-oximeters. The AVL Omni 6, CC270, IL482, IL682, and OSM3 are conventional CO-oximeters that hemolyze blood samples before analyzing them. In contrast, the AVOXimeters 1000 and 4000 and the IL Synthesis 35 make their measurements without hemolyzing the samples. Because perflubron is expected to be used most frequently on surgical patients in a hemodiluted state, we conducted all tests on human erythrocytes suspended in plasma at a hemoglobin concentration standardized to 70 g/L (7 g/dL) and with oxyhemoglobin saturation set at 97%. When perflubron was added to the blood samples, the nonhemolyzing CO-oximeters were not seriously affected by perflubron concentrations in and above the therapeutic range. In contrast, some of the hemolyzing CO-oximeters experienced concentration-dependent interference in their measurements of all analytes except total hemoglobin concentration. Thus, we conclude that the nonhemolyzing CO-oximeters provide an effective means for determining whether a hemolyzing COoximeter is experiencing clinically important interference in blood from patients receiving perflubron.
Perflubron emulsion (Oxygent TM ) is now in advanced clinical trials as a non-hemoglobin, oxygen-carrying blood substitute and is expected to be in clinical use soon. A preliminary report (1) indicates that this fluorocarbon emulsion, like its predecessors (2) (3) (4) , interferes with the spectrophotometric measurements of CO-oximeters. In many different hospital settings, ranging from intensive care units to emergency rooms, oximeters and CO-oximeters are commonly used to analyze blood samples to obtain clinical assessments of oxygen transport in critically ill patients. Therefore, clinicians, laboratorians, and clinical chemists need to be aware of the limitations of these instruments and the extent to which their measurements are influenced by fluorocarbon emulsions such as perflubron. The purpose of this study was to quantify the interference of perflubron in the measurements of eight widely used oximeters and CO-oximeters. Our study included conventional CO-oximeters that hemolyze each blood sample before analyzing it and newer instruments that make their measurements directly in unaltered whole blood without hemolysis.
Materials and Methods description of perflubron emulsion
Perflubron is the generic name for 1-bromo-1,1,2,2,3,3,4,4,5, 5,6,6,7,7,8,8,8-heptadecafluorooctane . As the chemical name denotes, perflubron is an eight-carbon aliphatic molecule with all hydrogen atoms replaced by fluorine except for a single bromine atom at one end of the chain. At a Po 2 of 500 mmHg, Ͼ160 mL O 2 /L can dissolve in a 900 g/L emulsion of perflubron. According to the manufacturer (Alliance Pharmaceutical Corp., San Diego, CA), the current formulation of perflubron-based emulsion (AF0144) is a 600 g/L perfluorocarbon emulsion that contains egg yolk phospholipid as an emulsifier (5) . The material is dispensed in 100-mL containers and has a milky white appearance. The fluorocarbon droplets in the emulsion have a median diameter of 0.2 m and a specific gravity of 1.92. The interference of perfluorocarbon on a wide variety of common clinical laboratory tests has been reported previously (6) . A recent review of published preclinical studies has summarized the pharmacokinetics of perflubron, its side-effects, and its efficacy as a temporary oxygen carrier (5) .
instruments evaluated
In this study we assessed the effects of perflubron emulsion on the performance of eight widely used oximeters and CO-oximeters: the AVL Omni 6, AVL Scientific Corporation; the AVOXimeters 1000 and 4000, Avox Systems, Inc.; the CC270 CO-Oximeter, Ciba Corning Diagnostics Corp (now Chiron); the IL482 and IL682 CO-Oximeters and the IL Synthesis 35, Instrumentation Laboratory; and the OSM3 Hemoximeter, Radiometer America, Inc.
The AVL Omni 6, CC270, IL482, IL682, and OSM3 are conventional CO-oximeters that first hemolyze the blood sample before analyzing it to eliminate the light scattering caused by red blood cells. Therefore, we shall refer to these particular instruments as hemolyzing CO-oximeters. By contrast, the AVOXimeters 1000 and 4000 and the IL Synthesis 35 are relatively new devices that make their measurements directly in unaltered blood without hemolysis. Hence, we shall refer to this group of instruments as nonhemolyzing CO-oximeters. The IL Synthesis aspirates each blood sample in a manner similar to conventional CO-oximeters, whereas the AVOXimeters 1000 and 4000 use disposable optical cuvettes that are first filled with the blood sample and then inserted into the instrument. A more detailed comparison of the designs, specifications, and operating characteristics of all eight instruments can be found elsewhere (7).
other materials
The human blood used in this study was taken from hospital patients for routine diagnostic purposes and was provided to us in accordance with a protocol approved by the Institutional Review Board of the University of Texas Health Science Center. Standardized hemoglobin solutions (Multi-4 TM CO-Oximetry Controls) were obtained from Instrumentation Laboratory.
sample preparation
We sought to assess the effects of perflubron on the performance of the CO-oximeters under conditions that simulated the anticipated clinical use of this blood substitute. Because perflubron will be administered most frequently to surgical patients who have experienced substantial blood loss, have received perflubron emulsion and other fluids for volume replacement, and thus are in a hemodiluted state, we standardized our blood samples at a total hemoglobin concentration of 70 g/L (7 g/dL), i.e., at an hematocrit of ϳ20%. To do so, we centrifuged the original heparinized, arterial blood samples from hospital patients to separate red blood cells from plasma and then re-mixed red cells and plasma in appropriate proportions to obtain stock blood samples with a total hemoglobin concentration adjusted to 70 g/L (7 g/dL). If their oxyhemoglobin fractions were not already ϳ97%, we tonometered these standardized blood samples briefly with room air to bring them to that percentage. Oxygenating the blood in this manner also ensured that subsequent handling and the addition of the perflubron emulsion did not inadvertently alter the oxyhemoglobin concentration. After initially obtaining somewhat erratic readings, we found that more than usual effort was required to keep the blood samples sufficiently well mixed, and we assumed that this precaution was necessary because the fluorocarbon droplets, which are nearly twice as dense as water, tend to precipitate rapidly without continuous agitation to keep them in suspension.
experimental protocol
After the blood samples were prepared in the previously described manner, they were then analyzed on each of the instruments being tested. Subsequently, starting with 1 part of 60% emulsion in 20 parts of blood, perflubron emulsion was added in increasing amounts to the blood samples, and the measurements were repeated on each instrument until the final concentration of perflubron in blood exceeded the maximum anticipated therapeutic concentration. In this study, the concentration of perflubron ranged from 0 to 81. 
data analysis
To analyze the data, we plotted the measured values of each analyte vs the known concentrations of perflubron. As Figs. 1-4 show, our graphs are similar to the "interferographs" described by Glick et al. (8) except that the values on the ordinate were not normalized to the initial value because the fractions of the various hemoglobin species are already percentages. Because we had limited access to the IL682 and the AVL Omni 6, each data point on the graphs for these two instruments is the mean of two measurements. However, all of the other data points on the graphs represent the mean of five measurements on each of the other instruments. In Figs 
instrument operation
The calibration of each of the eight instruments under test was confirmed by taking readings on appropriate control material, and each instrument was operated in accordance with the manufacturer's instructions. The hemolyzing instruments were operated in the routine sampling mode rather than the "micro" mode. When the blood samples were analyzed on the AVOXimeters 1000 and 4000, the disposable optical cuvettes were filled, inspected for air bubbles and external blood or debris, and then inserted promptly (within a few seconds) into the instrument.
At the two highest perflubron concentrations, the OSM3 and the IL682 reported an error message indicating high turbidity; however, we recorded all readings regardless of whether an error condition was indicated. Only a limited number of measurements could be obtained from the AVL Omni 6 because it displayed multiple question marks as error messages and did not report the hemoglobin fractions at any of the perflubron concentrations except the lowest one.
Results

oxyhemoglobin fraction
The results we obtained with the eight instruments being tested when the concentration of perflubron was increased progressively from 0 to 81.7 g/L (8.17 g/dL) are shown in Fig. 1 . As Fig. 1 (upper panel) shows, the Radiometer OSM3 and the AVL Omni 6 experienced the greatest interference in their oxyhemoglobin measurements. At the lowest perflubron concentration, the readings of the AVL fell spuriously from a control value of 96.0% to 83.7% saturation. At higher perflubron concen- trations, the AVL showed question marks as error messages but gave no readings of oxyhemoglobin. Measurements of oxyhemoglobin on the OSM3 fell spuriously from a control value of 96.8% to 79.1% at the highest concentration of perflubron. The IL482 was the instrument next most severely affected. The percent saturation on the IL482 fell from 96.7% to 90.4% at the highest perflubron concentration. As Fig. 1 (lower panel) shows, the analyzers least affected by perflubron were the nonhemolyzing instruments: the AVOXimeters 1000 and 4000 and the IL Synthesis. Among the hemolyzing CO-oximeters, the IL682 and the CC270 were also relatively unaffected by perflubron.
carboxyhemoglobin fraction
The measurements of the carboxyhemoglobin fraction made by seven of the eight test instruments are shown in Fig. 2 . In the case of this analyte, the instruments most severely affected by perflubron were the OSM3 and the AVL, as the upper panel of Fig. 2 shows. Carboxyhemoglobin readings on the OSM3 rose spuriously from 0.5% to 13.2% at the highest concentration of perflubron. The AVL gave no carboxyhemoglobin readings except at the lowest perflubron concentration. In contrast, the nonhemolyzing instruments, the AVOXimeter 4000 and the IL Synthesis, were virtually unaffected by even the highest concentration of perflubron. To be more specific, mea- surements on the AVOXimeter 4000 fell from 1.5% to 1.3%. Among the hemolyzing CO-oximeters, the IL482, IL682, and the CC270 were also not appreciably affected by perflubron. For example, measurements on the IL482 increased from 1.2% to 1.6%. Readings on the CC270 fell appreciably only at the highest concentration of perflubron. No data are shown for the AVOXimeter 1000 because it does not report the fractions of carboxy-or methemoglobin.
methemoglobin fraction
The measurements of the methemoglobin fraction made by seven of the eight test instruments are shown in Fig. 3 . In the case of methemoglobin measurements, the instrument most severely affected by perflubron was the OSM3; its methemoglobin readings rose in a concentration-dependent manner from a control value of 1.2% to 8.4% at the highest concentration of perflubron. The AVL showed question marks as error messages but gave no readings of methemoglobin at perflubron concentrations above 28 g/L (2.8 g/dL). The IL482 was less severely affected; its methemoglobin measurements rose from 0.3% to 4.8%. The other instruments were even less affected by perflubron. For example, methemoglobin measurements on the AVOXimeter 4000 rose from a control value of 0.9% to 1.4% at the highest concentration of perflubron. Similarly, values on the IL Synthesis rose by only 1.3%. 
total hemoglobin concentration
The effect of perflubron on the total hemoglobin measurements made by the test instruments is shown in Fig. 4 . Neither the hemolyzing (upper panel) nor the nonhemolyzing instruments (lower panel) were seriously affected by even the highest concentration of perflubron. To be specific, hemoglobin readings on the OSM3 fell in a concentration-dependent manner from a control value of 71 g/L (7.1 g/dL) to 66 g/L (6.6 g/dL) at the highest concentration of perflubron, and those on the IL682 increased from 70 g/L (7.0 g/dL) to 77 g/L (7.7 g/dL). Readings on the nonhemolyzing IL Synthesis rose in a concentration-dependent manner by 6 g/L (0.6 g/dL).
Readings on the AVOXimeters 1000 and 4000 and CC270 remained within 4 g/L (0.4 g/dL) of the control value.
As Fig. 4 shows, all eight instruments were slightly affected by perflubron; however, none of the perflubroninduced errors was likely to be clinically significant. For example, the reading of the total hemoglobin concentration on the OSM3 was only 5 g/L (0.5 g/dL) lower than control at the highest concentration of perflubron. Of course, an absolute error of 5 g/L (0.5 g/dL) is only a 3.3% error at a total hemoglobin concentration of 150 g/L (15 g/dL), and in a hemodiluted patient with a total hemoglobin concentration of 70 g/L (7 g/dL) is still only a 7.1% error. 
Discussion caveats and limitations
A preliminary report had demonstrated that perflubron interferes with the IL482 CO-oximeter (1). Therefore, we sought to assess the effects of perflubron on the performance of other newer, widely used CO-oximeters and to do so under conditions that simulated the most frequently anticipated clinical use of perflubron. Perflubron emulsion has two chief therapeutic effects: volume replacement to maintain the circulation and maintenance of the blood oxygen concentration through its oxygen-carrying ability. Because relatively little oxygen dissolves in fluorocarbons at a normal arterial Po 2 , increasing the inspired Po 2 is necessary to exploit the oxygen-carrying ability of perflubron. The standardized blood samples used in this study had a hemoglobin concentration of 70 g/L (7 g/dL) and were 97% saturated with oxygen. Thus, they simulated the arterial blood of surgical patients receiving perflubron and oxygen after experiencing substantial blood loss. As Figs. 1-4 show, standardizing the blood samples in this manner also greatly facilitated comparing one instrument with another. However, the interference of perflubron on the measurements of the hemoglobin fractions was inversely related to hematocrit in one study (1) . Thus, the effects of perflubron reported here may be greater than they would be at a normal hematocrit. This caveat does not apply to the measurements of total hemoglobin.
Because this study was designed to simulate the arterial blood of surgical patients receiving perflubron and oxygen, the concentrations of carboxy-and methemoglobin were low by design, i.e., in the 0 -3% range. Although our data demonstrate the directional effects of perflubron interference on each of the analytes shown in Figs. 1-4 , one should not extrapolate the present findings to markedly different conditions. For example, Figs. 1 and 2 show that perflubron causes the OSM3 to give spuriously low oxyhemoglobin readings and spuriously high carboxyhemoglobin readings when the true carboxyhemoglobin concentration is in the 0 -3% range. It is not known, however, if perflubron causes the OSM3 to give spuriously high carboxyhemoglobin concentrations when the carboxyhemoglobin concentration is actually 50%. A similar caveat applies to increased methemoglobin concentrations. Nevertheless, the data shown here should be useful under the intraoperative conditions in which perflubron emulsion will be most frequently be administered.
A third caveat regards the perflubron concentration range we studied. Perflubron is expected to be administered at a dose of 0.9 -2.7 grams of fluorocarbon per kilogram of body weight. Because the actual pharmacokinetics and blood volume of a patient are seldom known, it is difficult to predict the concentration that perflubron will actually reach even if the exact dose is known; however, by assuming an normal blood volume and typical ratios of blood volume to body weight, e.g., 7.5%, one can estimate that the therapeutic perflubron concentration range will be ϳ10 -40 grams of fluorocarbon per liter (ϳ1-4 grams of fluorocarbon per deciliter) of blood. Of course, it could be slightly higher if administered to an obese or hypovolemic patient. Thus, it is likely that the perflubron concentrations we studied [0 -80 g/L (0 -8 g/dL)] include and exceed the therapeutic range.
hemolyzing co-oximeters
In this study we examined the effects of perflubron on the performance of five of the most widely used conventional hemolyzing CO-oximeters (AVL, CC270, IL482, IL682, and OSM3) and on three relatively new instruments, the AVOXimeters 1000 and 4000 and the IL Synthesis. Conventional CO-oximeters like the OSM3 and the IL482 operate by aspirating a blood sample, hemolyzing the sample either ultrasonically (OSM3) or chemically (IL482) to eliminate the light scattering caused by red blood cells, and then subjecting the hemolyzed sample to multiwavelength spectrophotometry. Because hemolyzing COoximeters rely on hemolysis to eliminate light scattering in the sample, it was not surprising that several of them performed poorly in our tests. In fact, previous studies have shown that the measurements of conventional COoximeters are often seriously affected if emulsified, lightscattering particles like fluorocarbons (2-4) or lipids (9 -11) persist after the blood samples are hemolyzed.
In our tests the OSM3 and the AVL were the instruments most severely affected by the fluorocarbon emulsion. This result was not anticipated because the OSM3 measures the residual turbidity that persists in the hemolyzed sample. Although the turbidity corrections of the OSM3 were not sufficient to compensate for the additional light scattering caused by the perflubron emulsion, the OSM3 often indicated turbidity was high (see Materials and Methods). The performance of the AVL was more difficult to assess because it did not give readings at all perflubron concentrations; however, the sharp fall in its oxyhemoglobin reading at the lowest perflubron concentration (Fig. 1, upper panel) indicates that this instrument is not likely to be useful for clinical assessments of oxygen transport in patients receiving perflubron. Among the conventional hemolyzing CO-oximeters we tested, the CC270 was least affected by perflubron; only at the highest perflubron concentration did its readings of oxy-, carboxy-, and methemoglobin depart appreciably from the control reading (Figs. 1-3 , upper panels).
nonhemolyzing co-oximeters
As a group, the nonhemolyzing instruments were less affected by perflubron-containing blood samples than the conventional hemolyzing instruments. At all of the perflubron concentrations we studied, the AVOXimeters 1000 and 4000 and the IL Synthesis consistently gave clinically acceptable results for all of the analytes they measure (Figs. 1-4 , lower panels). These instruments are produced under license from the University of Texas, and Clinical Chemistry 44, No. 10, 1998 they are the first to make multiple spectrophotometric measurements directly in unaltered whole blood without first hemolyzing the sample (patents pending). The physical optics of these instruments were selected to maximize the true optical absorbance of intact blood and to minimize the contribution that light scattering makes to the total optical attenuation of nonhemolyzed blood. In addition, they use a sufficient number of wavelengths to assess the magnitude of light scattering in each sample and thus to correct for it using a series of effective algorithms. Moreover, it should be noted that the magnitude of light scattering in nonhemolyzed blood (12, 13) exceeds the relatively mild turbidity of hemolyzed blood by a factor of 20 -50. Therefore, we anticipated that the additional light scattering caused by perflubron emulsion would not appreciably affect the measurements made by the nonhemolyzing instruments. Because the nonhemolyzing instruments gave clinically acceptable measurements, particularly of oxyhemoglobin and total hemoglobin concentrations and thus of the hemoglobin-bound oxygen, these instruments are well-suited to assess oxygen transport in patients receiving perflubron therapeutically as a temporary oxygen carrier. Of course, when oxygen and therapeutic concentrations of perflubron are administered, measurements of Po 2 are also necessary to assess the oxygen in plasma and the substantial amount dissolved in the fluorocarbon. The precision, accuracy, and long-term stability of the AVOXimeters, as well as their ability to function without anticoagulants, have been reported in a series of recent publications (14 -16) . The IL Synthesis is so new that only a preliminary publication has reported its performance (17) .
Blood samples containing perflubron will present a challenge to laboratorians and clinical chemists. In fact, even using the present findings to correct the readings of a given instrument will be difficult because there is presently no convenient way to measure the concentration of perflubron in a patient's blood. Therefore, the soundest approach to assessing oxygen transport in these patients is to use one of the instruments shown here to be unaffected by even the highest concentrations of perflubron. Our findings also indicate that the nonhemolyzing CO-oximeters provide an effective means for determining whether a hemolyzing CO-oximeter is experiencing clinically significant interference in blood samples from patients receiving fluorocarbon emulsions.
